Retrospective study of the safety of caspofungin in immunocompromised pediatric patients

被引：38

作者：

Franklin, JA

McCormick, J

Flynn, PM

机构：

[1] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA

[2] St Jude Childrens Res Hosp, Dept Pharmaceut, Memphis, TN 38105 USA

[3] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Knoxville, TN 37996 USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2003年 / 22卷 / 08期

关键词：

caspofungin; pediatrics; antifungal; immunocompromised patients;

D O I：

10.1097/01.inf.0000078164.80233.14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Caspofungin is an antifungal medication proved efficacious and well-tolerated in adults. Twenty-five pediatric patients at St. Jude Children's Research Hospital who had received at least one dose of caspofungin were identified, and their records were reviewed retrospectively. Caspofungin was well-tolerated; only three patients experienced any adverse event judged possibly related to drug. Caspofungin appears to be safe in immunocompromised pediatric patients.

引用

收藏

页码：747 / 749

页数：3

相关论文

共 19 条

[1] Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice [J].

Abruzzo, GK ;

Gill, CJ ;

Flattery, AM ;

Kong, L ;

Leighton, C ;

Smith, JG ;

Pikounis, VB ;

Bartizal, K ;

Rosen, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2310-2318

[2] Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis [J].

Abruzzo, GK ;

Flattery, AM ;

Gill, CJ ;

Kong, L ;

Smith, JG ;

Pikounis, VB ;

Balkovec, JM ;

Bouffard, AF ;

Dropinski, JF ;

Rosen, H ;

Kropp, H ;

Bartizal, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2333-2338

[3]

[Anonymous], 1998, REVISED COMMON TOXIC

[4] Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases [J].

Arathoon, EG ;

Gotuzzo, E ;

Noriega, LM ;

Berman, RS ;

DiNubile, MJ ;

Sable, CA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :451-457

[5] In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. [J].

Arikan, S ;

Lozano-Chiu, M ;

Paetznick, V ;

Rex, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :245-247

[6] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].

Bartizal, K ;

Gill, CJ ;

Abruzzo, GK ;

Flattery, AM ;

Kong, L ;

Scott, PM ;

Smith, JG ;

Leighton, CE ;

Bouffard, A ;

Dropinski, JF ;

Balkovec, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332

[7] Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].

Boutati, EI ;

Anaissie, EJ .

BLOOD, 1997, 90 (03) :999-1008

[8] Update on antifungals targeted to the cell wall:: focus on β-1,3-glucan synthase inhibitors [J].

Georgopapadakou, NH .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (02) :269-280

[9] Caspofungin acetate: An antifungal agent [J].

Hoang, A .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (13) :1206-1214

[10] Caspofungin [J].

Keating, GM ;

Jarvis, B .

DRUGS, 2001, 61 (08) :1121-1129